Company News 

Sinclair Pharma enjoys uplifting end to 2017

Sinclair Pharma enjoys uplifting end to 2017

Shares in Sinclair Pharma (SPH) rose following a trading update released ahead of full-year results, which outlined 20 per cent sales growth over the prior year. Revenue also rose by a quarter in the latter half of the year, leaving the company on track to turn a maiden cash profit. Good sales growth was reported across most of the company's key products, notably a 12 per cent increase in sales of its most popular non-surgical treatment derma filler Silhouette Soft.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now